Omeros (OMER) FCF Margin (2010 - 2026)
Omeros recorded quarterly FCF Margin of 146.63% in Q1 2026, down 85.13% quarter-over-quarter from 79.2% in Q3 2021.
Omeros' FCF Margin history runs 13 years deep, the most recent figure standing at 146.63% for Q1 2026.
- In Q1 2026, FCF Margin changed N/A year-over-year to 146.63%; the TTM figure through Mar 2026 stood at 137.93% (up 4109.0% YoY), while the FY2020 annual figure was 135.98%, down 8195.0% from the prior year.
- FCF Margin came in at 146.63% for Q1 2026 at Omeros, down from 79.2% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 146.63% in Q1 2026 to a low of 146.63% in Q1 2026.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -3.98% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 43.35% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 23.53% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.17% |
| 10 | Omeros | 772.03 Mn | 636.71 Mn | 9.31 Mn | -146.63% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -146.63% |
| Sep 30, 2021 | -79.20% |
| Jun 30, 2021 | -96.03% |
| Mar 31, 2021 | -191.19% |
| Dec 31, 2020 | -173.13% |
| Sep 30, 2020 | -134.08% |
| Jun 30, 2020 | -278.94% |
| Mar 31, 2020 | -39.12% |
| Dec 31, 2019 | -68.92% |
| Sep 30, 2019 | -25.32% |
| Jun 30, 2019 | -62.37% |
| Mar 31, 2019 | -60.29% |
| Dec 31, 2018 | -112.41% |
| Sep 30, 2018 | -802.13% |
| Jun 30, 2018 | -1,879.94% |
| Mar 31, 2018 | -722.86% |
| Dec 31, 2017 | -30.32% |
| Sep 30, 2017 | -51.84% |
| Jun 30, 2017 | -48.99% |
| Mar 31, 2017 | -104.22% |
| Dec 31, 2016 | -84.55% |
| Sep 30, 2016 | -99.76% |
| Jun 30, 2016 | -128.24% |
| Mar 31, 2016 | -224.13% |
| Dec 31, 2015 | -249.48% |
| Sep 30, 2015 | -449.86% |
| Jun 30, 2015 | -522.72% |
| Mar 31, 2015 | -4,504.12% |
| Dec 31, 2014 | -8,726.11% |
| Sep 30, 2014 | -7,454.21% |
| Jun 30, 2014 | -33,928.89% |
| Mar 31, 2014 | -11,145.00% |
| Dec 31, 2013 | -214.79% |
| Sep 30, 2013 | -5,656.12% |
| Jun 30, 2013 | -6,710.00% |
| Mar 31, 2013 | -827.03% |
| Dec 31, 2012 | -833.29% |
| Sep 30, 2012 | -528.65% |
| Jun 30, 2012 | -585.45% |
| Mar 31, 2012 | -372.79% |
| Dec 31, 2011 | -647.59% |
| Sep 30, 2011 | -416.82% |
| Jun 30, 2011 | -591.86% |
| Mar 31, 2011 | -690.64% |
| Dec 31, 2010 | 673.57% |
| Sep 30, 2010 | -2,382.68% |